ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: Ono Pharmaceutical Co. Ltd is conducting a Phase II study titled A Multicenter, Open-label, Uncontrolled Phase II Study to Investigate Efficacy and Safety of ONO-4538 in Patients With Rhabdoid Tumor. The study aims to assess the efficacy and safety of ONO-4538 in treating rhabdoid tumors, a rare and aggressive cancer, highlighting its potential significance in oncology.
Intervention/Treatment: The study tests ONO-4538, an experimental drug administered every two weeks, designed to treat rhabdoid tumors by targeting specific cancer pathways.
Study Design: This interventional study follows a single-group model without masking, focusing on treatment as the primary purpose. Participants receive the drug ONO-4538, with outcomes measured for efficacy and safety.
Study Timeline: The study began recruiting on September 30, 2024, with the latest update submitted on June 1, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
Market Implications: The ongoing study of ONO-4538 could significantly impact Ono Pharmaceutical’s stock performance, especially if results show positive outcomes. Success may enhance investor sentiment and position Ono favorably against competitors in the oncology sector.
The study is currently recruiting, with ongoing updates available on the ClinicalTrials portal.